Caplin Point Laboratories Set to Report Q2 FY27 on November 12

Caplin Point Laboratories Limited is scheduled to report its Q2 FY27 results on November 12, 2026, following Q1 sales of ₹610 crore and net profit of ₹179 crore, up 19% year-on-year. The board is due to consider the July-September 2026 financial statements, followed by an earnings call at 4:30 pm IST.

When will Caplin Point Laboratories announce Q2 FY27 results?

Caplin Point Laboratories will announce its Q2 and first-half FY27 financial results on Thursday, November 12, 2026. The company informed the exchanges through an NSE filing dated November 2 that its board would meet on that day to approve the results for the quarter ended September 30, 2026.

The results cover the July-September 2026 period. Caplin Point has also scheduled an earnings conference call at 4:30 pm IST on November 12, after the results announcement, to discuss financial performance and business outlook. The company had earlier announced the closure of its trading window from October 1 for finalisation of the Q2 results.

The reported schedule resolves earlier uncertainty around the date. Information published before the November 2 exchange filing had stated that no board-meeting intimation was available as of September 17 and identified November 14, 2026 as the statutory outer deadline for September-quarter results. The subsequent filing established November 12 as the board-meeting date.

What was Caplin Point Laboratories' performance in Q1 FY27?

Caplin Point reported Q1 FY27 sales of ₹610 crore, EBITDA of ₹213 crore and net profit of ₹179 crore for the quarter ended June 2026. Sales increased 20% from ₹510 crore in the June 2025 quarter, while EBITDA also rose 20% from ₹178 crore and net profit increased 19% from ₹151 crore.

Earnings per share for the June 2026 quarter stood at ₹23.27, compared with ₹20.10 a year earlier. On a sequential basis, sales rose from ₹600 crore in March 2026, EBITDA increased from ₹204 crore and net profit was higher than ₹173 crore. The reported Q1 EBITDA margin was 38.4%.

A separate quarterly financial-data table shows total income of ₹643.91 crore for June 2026, compared with ₹628.52 crore in March 2026 and ₹533.36 crore in June 2025. The distinction between sales and total income is relevant because the figures are presented under different financial line items in the available data.

What comparison will matter for Caplin Point's Q2 FY27 numbers?

Caplin Point's September 2026 results will be assessed against Q2 FY26 revenue of ₹534 crore and profit of ₹160 crore. These were the reported figures for the quarter ended September 2025, providing the direct year-on-year base for the upcoming release.

The June 2026 quarter provides the most recent sequential reference point, with sales at ₹610 crore and profit at ₹179 crore. However, no verified numerical consensus estimate for the September 2026 quarter is included in the available information. As a result, the company's reported revenue, margins, profit and operational commentary will be the primary data points for investors when the results are released.

Market material also cited full-year FY27 revenue consensus of ₹2,490 crore, representing 13.8% growth from FY26 revenue of ₹2,187 crore. On that basis, the next three quarters would need to average about ₹626 crore in revenue. This is a market expectation cited in the provided material, not guidance issued by Caplin Point.

Which business and financial indicators should investors track?

Investors should track sales growth, EBITDA margin, net profit and the progress of Caplin Steriles when Caplin Point releases Q2 FY27 numbers. In the Q1 earnings-call summary, the company reported that its US subsidiary, Caplin Steriles, recorded revenue of ₹43.1 crore after tripling its revenue year-on-year.

The same summary said gross margin was 59.8%, above a 55% target, and that the company had no external debt. These indicators provide context for profitability and balance-sheet discussion on the November 12 call, alongside the consolidated quarter's reported margin performance.

For the full year, available consolidated data showed operating profit before other income, interest and exceptional items of ₹247.03 crore. Other income was ₹33.55 crore, while interest expense was ₹0.18 crore. Full-year cost data included raw-material costs of ₹732.28 crore, employee costs of ₹177.15 crore, depreciation of ₹21.62 crore and other expenses of ₹396.88 crore.

How does the Q2 FY27 schedule affect Caplin Point investors?

The November 12 announcement gives investors a confirmed date for assessing whether Caplin Point's Q1 growth trends continued through the September quarter. The release will also provide first-half FY27 figures, enabling a comparison of reported performance with the cited full-year revenue expectation of ₹2,490 crore.

The company has not disclosed Q2 revenue or profit before the board meeting. Therefore, movement in financial metrics, margin performance and comments on Caplin Steriles will need to be evaluated only after the exchange filing and the scheduled earnings call. The trading-window closure announced from October 1 is part of the results-finalisation process disclosed by the company.

Conclusion

Caplin Point will report Q2 FY27 results on November 12 after delivering 20% year-on-year sales growth and 19% net-profit growth in Q1 FY27. The September-quarter release will be compared primarily with the year-ago base of ₹534 crore in revenue and ₹160 crore in profit, while the June-quarter performance offers the latest sequential benchmark.

The next confirmed event is Caplin Point's Q2 and H1 FY27 earnings conference call at 4:30 pm IST on November 12. Investors will watch the reported September-quarter financials, EBITDA margin, Caplin Steriles performance and management's business outlook disclosed during that call.